Array BioPharma Inc. (NASDAQ:ARRY) is set to post its quarterly earnings results before the market opens on Wednesday, August 2nd. Analysts expect Array BioPharma to post earnings of ($0.21) per share for the quarter.

Array BioPharma (NASDAQ:ARRY) last announced its quarterly earnings results on Wednesday, May 10th. The biopharmaceutical company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by $0.05. The company had revenue of $33.28 million during the quarter, compared to analyst estimates of $38.28 million. Array BioPharma’s quarterly revenue was down 22.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.16) earnings per share. On average, analysts expect Array BioPharma to post $-0.76 EPS for the current fiscal year and $-0.89 EPS for the next fiscal year.

Shares of Array BioPharma Inc. (NASDAQ ARRY) opened at 7.86 on Wednesday. Array BioPharma Inc. has a 52 week low of $3.10 and a 52 week high of $13.40. The company has a 50-day moving average price of $8.27 and a 200 day moving average price of $9.30. The firm’s market cap is $1.34 billion.

TRADEMARK VIOLATION NOTICE: “Array BioPharma Inc. (NASDAQ:ARRY) Scheduled to Post Earnings on Wednesday” was published by American Banking News and is the property of of American Banking News. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/07/26/array-biopharma-inc-nasdaqarry-scheduled-to-post-earnings-on-wednesday.html.

Several equities research analysts recently weighed in on ARRY shares. Vetr raised Array BioPharma from a “buy” rating to a “strong-buy” rating and set a $10.26 price objective on the stock in a report on Wednesday, March 29th. ValuEngine raised Array BioPharma from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. J P Morgan Chase & Co raised Array BioPharma from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $9.00 to $10.00 in a report on Wednesday, May 3rd. Cantor Fitzgerald reissued a “buy” rating and set a $13.00 price objective on shares of Array BioPharma in a report on Tuesday, July 18th. Finally, Jefferies Group LLC reissued a “buy” rating and set a $8.00 price objective on shares of Array BioPharma in a report on Wednesday, March 29th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and seven have given a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $11.54.

Array BioPharma Company Profile

Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).

Earnings History for Array BioPharma (NASDAQ:ARRY)

Receive News & Ratings for Array BioPharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array BioPharma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.